Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
27 articles
Newest firstCannabidiol (CBD) has attracted growing scientific and clinical interest due to its potential therapeutic applications and increasing availability across Europe. This narrative review examined the regulatory status, market availability, and clinical use of CBD in Croatia in relation to selected European Union countries and international reference models (Canada and Australia). A literature search was conducted usi…
Open article record in new tab ↗Since federal legalisation in November 2016, Australia’s medical cannabis regulation has evolved into a complex framework that involves the Therapeutic Goods Administration, state health departments, and multiple professional oversight bodies. This narrative review examines the policy hurdles and coordination gaps that have emerged between 2016 and 2024, providing a longitudinal perspective on the ongoing debate.…
Open article record in new tab ↗Abstract Cannabis remains the most widely used illicit substance in the United States, specifically among young adults. Previous research identifies emotion dysregulation as a predictor of cannabis use, yet there remains some uncertainty in the literature regarding which facets of emotion dysregulation are the most important in relation to cannabis use. Indeed, the studies that have compared the facet-level associ…
Open article record in new tab ↗There is concern about the quality of cannabis-based products used in Brazil, mainly cannabidiol (CBD). This study aimed to evaluate the quality of labeling on CBD products marketed in Brazil authorized by two regulations - N660/2022 on imported products and N327/2019 on products with temporary trade permits - and whether there were differences between them concerning four domains: prescription, good manufacturing…
Open article record in new tab ↗Background and purpose Epilepsy is a common indication for medicinal cannabis (MC) prescription in Australia. Despite legal MC products being available for 8 years, some individuals continue to rely on illicit cannabis. Here, we conducted a survey of Australian persons/people with epilepsy (PWE) and caregivers of a PWE to assess whether the current legal framework supports PWE and/or their caregivers to access pre…
Open article record in new tab ↗Objectives Rapid growth in the cannabidiol (CBD) market has been temporally associated with increasing emergency department (ED) visits related to cannabis exposure in young children. This study examined the prevalence of CBD products among individuals with and without children in the household and described their general perceptions of CBD products to assess potential risks to children. Methods A prospective obse…
Open article record in new tab ↗Background/Objectives: Recent evidence supporting the medicinal use of cannabis has brought significant regulatory changes regarding its legal status, cultivation, and use. Several countries have adopted regulatory strategies enabling access to cannabis-based medicinal products; however, the regulation and availability of high-quality cannabis products differs globally. This work aimed to explore the regulatory pa…
Open article record in new tab ↗Introduction This study investigated exposures involving ∆8-tetrahydrocannabinol (∆8-THC) reported to US poison centers (PCs), including variation among states and regions. It evaluated whether the ∆8-THC exposure rate was lower among states with ∆8-THC regulations and states where cannabis (∆9-THC) use was legal. Methods National Poison Data System data for ∆8-THC exposures in 2021-2022 were analyzed, including c…
Background Canada legalized recreational cannabis in 2018, and one of the primary objectives of the Cannabis Act was to protect youth by reducing their access to cannabis and providing public education. Canada has the highest prevalence of cannabis use worldwide, particularly among youth and young adults under the age of 25. Cannabis use is linked with many adverse effects for youth and young adults including psyc…
With widely divergent state and federal regulations and a history of suspect brands and illicit markets, derived psychoactive cannabis products (DPCPs) face contested discourse as to their content, quality, and safety. We conducted exploratory research on public-health related factors related to brand quality including assessing potential counterfeit products, website and social media presence, third party laborat…
Open article record in new tab ↗Background Suk-Saiyasna is a traditional Thai herbal remedy that comprises 12 distinct herbs. Among these, cannabis leaves constitute 12 of the total 78 components in this formulation. This study specifically examines the portion of the cannabis plant, which accounts for approximately 15.8% of the overall herbal composition used in the entire remedy. According to the Thailand Narcotics Act of 2022, the Δ9-tetrahyd…
Open article record in new tab ↗BackgroundChanges in regulation for cannabis for nonmedical use (CNMU) are underway worldwide. Switzerland amended the law in 2021 allowing pilot trials evaluating regulative models for cannabis production and distribution. Simultaneously, cannabis for medical use (CMU) in psychiatry is a growing issue, asked for by patients and being discussed by medical professionals.MethodsFrom December 2021 to February 2022, w…
Open article record in new tab ↗Background The reintroduction of Cannabis sativa L. in the form of hemp (< 0.3% THC by dry weight) into the US agricultural sector has been complex and remains confounded by its association with cannabis (> 0.3% THC by dry weight). This has been further exacerbated by inconsistent hemp regulations in the US since the 2014 Farm Bill's reintroduction. Methods A content analysis was performed to analyze the terms and…
Increase in medical cannabis use, along with available products, warrants the need for clinicians to be knowledgeable in evaluating the quality of any cannabis product presented in clinical practice. Determining whether a product is regulated within the region is key in assessing overall quality and safety. Regulated products are held to a higher standard including independent testing, contamination mitigation, an…
Open article record in new tab ↗A regulatory framework allowing legal access to medicinal cannabis (MC) products has operated in Australia since November 2016. MC prescribing by healthcare practitioners (HCPs) is primarily conducted through the Special Access Scheme - Category B (SAS-B) pathway, through which prescribers apply to the Therapeutic Goods Administration (TGA-the federal regulator) for approval to prescribe a category of product to a…
Purpose of review The purpose of this review was to describe the state-of-the-literature on research specific to cannabis vaping among youth and young adults. Recent findings Out of 1801 records identified, a total of 202 articles met eligibility criteria for inclusion in this review. Most of this literature (46.0% of studies) was specific to the health effects of cannabis vaping, particularly EVALI (e-cigarette a…
Open article record in new tab ↗Background In recent decades, several political, legislative, judicial, consumer, and commercial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As the use of MC evolves through legislative reform, with an increase in public acceptance and therapeutic potential, a need exists to further investigate the facilitators and barriers to MC regulation. Methods A scoping…
Open article record in new tab ↗Medical cannabis represents a potential route of pesticide exposure to susceptible populations. We compared the qualifying conditions for medical use and pesticide testing requirements of cannabis in 33 states and Washington, D.C. Movement disorders were the most common neurological category of qualifying conditions, including epilepsy, certain symptoms of multiple sclerosis, Parkinson's Disease, and any cause of…
Open article record in new tab ↗BACKGROUND: Although illegal in most countries, cannabis remains the most common illicit drug in Switzerland and worldwide. While there is growing evidence on adverse effects of cannabis use, most users do not report any problems or negative consequences. In the face of a sustained high prevalence of cannabis use and the recent legalization waves in different parts of the world, it is important to know how cannabi…
Open article record in new tab ↗The object of this contribution based on a systematic review of the literature is to examine to what degree the level of use and potency play a role in regulatory policies for alcohol, other psychoactive substances and gambling, and whether there is an evidence base for this role. Level of use is usually defined around a behavioural pattern of the user (for example, cigarettes smoked per day, or average ethanol us…